Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT01141244
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States
🇺🇸C S Mott Children's Hospital, Ann Arbor, Michigan, United States
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
- Conditions
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT01122615
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT01111825
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸Western Regional Medical Center, Inc., Goodyear, Arizona, United States
Temsirolimus in Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 20
- Registration Number
- NCT01111448
- Locations
- 🇩🇪
Universitätsmedizin Göttingen Georg-August-Universität Abteilung Hämatologie und Onkologie, Goettingen, Germany
🇩🇪Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klin. Immunologie, Düsseldorf, Germany
🇩🇪Universitätsklinikum Leipzig AöR, Leipzig, Germany
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
- Conditions
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 15
- Registration Number
- NCT01090466
- Locations
- 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 249
- Registration Number
- NCT01087554
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT01083368
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸CCF-Willoughby Hills, Willoughby Hills, Ohio, United States
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 6
- Registration Number
- NCT01079767
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Henri Mondor, Creteil, France
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 110
- Registration Number
- NCT01076543
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Susana M. Campos, MD
- Target Recruit Count
- 11
- Registration Number
- NCT01065662
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.